Form 4: Apogee Therapeutics CEO Michael Henderson Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Apogee Therapeutics CEO Michael Henderson sold 15,000 shares of common stock on November 6, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Michael Henderson, CEO of Apogee Therapeutics, sold 14,000 shares of common stock at a weighted average price of $59.17 on November 6, 2024.
- An additional 1,000 shares were sold at a price of $59.94 on the same day.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.
- Following the reported transactions, Henderson beneficially owns 1,339,487 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports stock sales under a pre-arranged plan, which is a common practice.
Industry Context
Sales by insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time without being accused of trading on inside information. The market will likely view this as a routine transaction.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, but is unlikely to have a significant impact due to the pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 2023-09-25 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2024-11-06 | Date of stock sale transactions. |
| 2024-11-08 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.